Trial Profile
A Single-Center, Randomized, Observer-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5469754, a Humanized Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2014
Price :
$35
*
At a glance
- Drugs RO-5469754 (Primary) ; RO-5469754 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Roche
- 09 Apr 2014 New trial record